An Open Prospective Trial of IV Ketamine in Suicidal Adolescents
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02048423|
Recruitment Status : Unknown
Verified January 2014 by Nationwide Children's Hospital.
Recruitment status was: Recruiting
First Posted : January 29, 2014
Last Update Posted : January 29, 2014
- Investigate the safety and effectiveness of a single dose of IV Ketamine for adolescents with suicidal ideation and depression. It is hypothesize that Ketamine will be well tolerated and significantly reduce depressive symptoms and suicidal ideation.
- Explore whether decision making as measured by the Iowa Gambling Task changes before and after Ketamine infusion. It is hypothesize that IV Ketamine infusion will significantly improve the decision making ability a measured by the Iowa Gambling Task in adolescents that are suicidal.
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder||Drug: Ketamine||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Prospective Trial of IV Ketamine in Suicidal Adolescents|
|Study Start Date :||June 2013|
|Estimated Primary Completion Date :||June 2015|
|Estimated Study Completion Date :||June 2015|
IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
- Change in Quick Inventory of Depression Clinician (QIDS-C) total scores from baseline to endpoint and Clinical Global Improvement Score. [ Time Frame: 2 days ]
- Clinical Global Assessment Scale [ Time Frame: 2 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02048423
|Contact: Robert A Kowatch, MD, PhDfirstname.lastname@example.org|
|Contact: Melinda Helton, Pharm||614-722-2607|
|United States, Ohio|
|Nationwide Children's Hospital||Recruiting|
|Columbus, Ohio, United States, 43205|
|Contact: Melinda Helton, RN 614-722-2607|
|Principal Investigator:||Robert A Kowatch, MD, PhD||OSU Medical Center/Nationwide Childrens Hospital|